Patents Examined by Allison Fox
  • Patent number: 9149048
    Abstract: The present invention relates to a lactase solution comprising a lactase solution comprising less than 10 g/kg of poly and oligosaccharides, a process for the production of such a lactase solution from an untreated lactase solution, a sterilized lactase, whereby such lactose is filter sterilized in-line with the milk production process.
    Type: Grant
    Filed: May 5, 2011
    Date of Patent: October 6, 2015
    Assignee: DSM IP ASSETS B.V.
    Inventors: Rudolf Franciscus Wilhelmus Cornelis Van Beckhoven, Petrus Andreas Van Paridon
  • Patent number: 9149514
    Abstract: A composition of lysozyme and a pharmaceutically acceptable carrier is active against the papilloma virus in both humans and animals. The composition can be used to treat women suffering from cervical cancer. The composition can also be used to treat cows and horses suffering sarcoids.
    Type: Grant
    Filed: October 15, 2010
    Date of Patent: October 6, 2015
    Assignee: MURAMI PHARMA, INC
    Inventor: Stefano Ferrari
  • Patent number: 9144588
    Abstract: Biologically pure cultures of Bacillus subtilis were isolated from the pericarp of nixtamalized corn. The Bacillus microorganisms were characterized and found to produce novel peptides which have antimicrobial activity. The Bacillus microorganisms are active against Gram-positive bacteria and may be used as an agent to prevent spoilage in foods. The Bacillus microorganisms may be included in probiotic food compositions to help maintain healthy gastrointestinal flora and modulate animal digestion.
    Type: Grant
    Filed: September 14, 2011
    Date of Patent: September 29, 2015
    Assignee: INVESTIGACION DE TECNOLOGIA AVANZADA, S.A. DE C.V.
    Inventors: Felipe A. Rubio, Manuel J. Rubio, Roberto Contreras, J. Fernando Ramirez
  • Patent number: 9144586
    Abstract: Various embodiments of the invention provide methods of treating diabetes and other glucose regulation disorders. In one embodiment, the method comprises removing L-cells from a donor, obtaining stem cells from a patient, and culturing the L-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived L-cells (SCDLC). An amount of the SCDLC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food. In another embodiment, the method comprises removing K-cells from a donor, obtaining stem cells from a patient, and culturing the K-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived K-cells (SCDKC). An amount of the SCDKC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food.
    Type: Grant
    Filed: April 7, 2011
    Date of Patent: September 29, 2015
    Assignee: INCUBE LABS, LLC
    Inventor: Mir Imran
  • Patent number: 9139811
    Abstract: The present invention relates to a composition for suppressing the death of stem cells during suspension culturing, a composition for mass culturing of stem cells, and a method for suppressing cell death of stem cells during suspension culturing. The composition of the present invention can be usefully used for effective single suspension culturing of stem cells, particularly, mesenchymal stem cells, or used for mass suspension culturing under the circumstances in which cell aggregation does not occur.
    Type: Grant
    Filed: December 27, 2011
    Date of Patent: September 22, 2015
    Assignee: SEOUL NATIONAL UNIVERSITY HOSPITAL
    Inventors: Eun Ju Lee, Hyo Soo Kim
  • Patent number: 9138465
    Abstract: The purpose of the present invention is to provide, in a simple and also inexpensive manner, a pharmaceutical composition which comprises a plurality of lysosomal enzymes and is effective in treating lysosomal storage disease caused by a deficiency in a plurality of lysosomal enzymes. Provided is a pharmaceutical composition for treating lysosomal storage disease, the composition comprising as an active ingredient a lysosomal enzyme group obtained from cells derived from a subject who does not suffer from lysosomal storage disease.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: September 22, 2015
    Assignee: OSAKA UNIVERSITY
    Inventors: Keiichi Ozono, Takanobu Otomo, Norio Sakai
  • Patent number: 9140688
    Abstract: A method of sex sorting sperm is disclosed. The sperm may be stained with a DNA selective fluorescent dye, which fluoresces when excited, a dead quenching dye, which selectively quenches fluorescence emitted by the DNA selective fluorescent dye within the membrane of compromised sperm, and a split enhancing dye. The stained sperm may then sorted into one or more gender enriched subpopulations of viable sperm.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: September 22, 2015
    Assignee: Inguran, LLC
    Inventors: Kenneth Michael Evans, Thomas B. Gilligan, Clara Gonzalez-Marin
  • Patent number: 9139814
    Abstract: This application relates to a serum-free culture medium that enables the proliferation of cell of the myogenic lineage while maintaining their ability to differentiate into functional muscle cells. Also contemplated herewith are method of culturing cells of the myogenic lineages and uses of the cultured cells for the treatment or the alleviation of symptoms of a muscular deficiencies.
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: September 22, 2015
    Assignee: Universite Laval
    Inventors: Victor-Alain Parent, Alain Garnier, Jacques P. Tremblay
  • Patent number: 9132156
    Abstract: Acellular amnion derived therapeutic compositions are described having a number of various compositional embodiments. An acellular amnion derived therapeutic composition has essentially no live or active amniotic stems cells. The amniotic stem cells may be destroyed, and the cells and cell debris may be removed from the acellular amnion derived therapeutic composition. An acellular amnion derived therapeutic composition may comprise micronized amniotic membrane particles, and/or amniotic fluid. An acellular amnion derived therapeutic composition may be a dispersion of micronized amniotic membrane combined with a fluid, such as plasma, saline, amniotic fluid, combinations thereof and the like. An acellular amnion derived therapeutic composition may be combined with a matrix component to form a composite. An acellular amnion derived therapeutic composition may be used in conjunction with a composition comprising viable cells, such as stem cells.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: September 15, 2015
    Inventors: Bruce Werber, Christian Beaudry, Terrell Suddarth
  • Patent number: 9119818
    Abstract: The invention provides a method of treating a disorder characterized by elevated or dysregulated myostatin, disorders where the interaction between follistatin and angiogenin can be used to improve function in tissues, neurological diseases or disorders, spinal injuries or diseases, bone diseases or disorders, diseases involving glucose homeostasis, wound healing, neuroprotection, nervous system functional support or managing metabolic diseases, the method comprising administering an effective amount of angiogenin or an angiogenin agonist. Compositions and neutraceuticals comprising angiogenin are also provided.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: September 1, 2015
    Assignees: AGRICULTURE VICTORIA SERVICES PTY LTD, Murray Goulburn Co-Operative Co., Limited
    Inventors: Matthew McDonagh, Benjamin Cocks, Angus Tester, Peter Hobman
  • Patent number: 9114190
    Abstract: Compositions and processes for the effective and efficient regeneration of spinal discs are provided. These compositions contain stem cells, donor cells, and platelet plasma compositions. By using these compositions, there is an increased likelihood of acceptance and proper cell differentiation.
    Type: Grant
    Filed: February 8, 2013
    Date of Patent: August 25, 2015
    Assignee: Laser Spine Institute, LLC
    Inventor: Mark Flood
  • Patent number: 9113641
    Abstract: The present invention provides methods for manufacturing heat treated products involving the use of probiotic bacteria, e.g. lactic acid bacteria and/or Bifidobacteria, cultures of such bacteria, supernatant from such cultures, and/or concentrates of such supernatant and/or fractions of such supernatant. The invention further provides heat treated products of such processes and their use for regulation of cellular uptake of fat and/or triglycerides and/or body weight management or weight reduction and/or redistribution of fat and/or reduction in visceral and/or abdominal fat deposition in a subject.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: August 25, 2015
    Assignee: Arla Foods amba
    Inventors: Velmurugesan Arulampalam, Joseph James Rafter, Sven Pettersson
  • Patent number: 9114191
    Abstract: A demineralized bone matrix is produced by a process in which a bone body is placed in a first processing solution comprising an acid to demineralize the bone body. The bone body is periodically removed from the first solution at specific time intervals to perform at least one test, such as a compression test, on a mechanical property of the bone body. When the test yields a desired result, the bone body is exposed to a second processing solution that is less acidic than the first, thus minimizing the exposure of the bone body to the harsh acidic conditions of the demineralization phase of the process.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: August 25, 2015
    Assignee: Bacterin International, Inc.
    Inventors: Nancy J. Shelby, Steven M. Scott, Benjamin P. Luchsinger, Gregory A. Juda, Kelly R. Kirker, Darrel L. Homes, Jesus Hernandez
  • Patent number: 9109204
    Abstract: The invention provides for a method for aggregating dermal papilla cells or dermal sheath cells or a combination thereof, the method comprising: growing dermal papilla cells or dermal sheath cells or a combination thereof in suspension culture; and contacting the culture with an effective amount of an enzyme, wherein a substrate of the enzyme is an extracellular matrix molecule in the suspension culture, so as to aggregate dermal papilla cells or dermal sheath cells. The culture may be a hanging drop culture and the enzyme may be a hyaluronidase.
    Type: Grant
    Filed: February 28, 2007
    Date of Patent: August 18, 2015
    Assignees: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, DURHAM UNIVERSITY
    Inventors: Angela M. Christiano, Colin A. B. Jahoda
  • Patent number: 9107942
    Abstract: The present invention is directed to methods of diagnosing and treating a fibrotic condition in a mammalian subject. These methods involve measuring the levels of trimethylation at lysine residue 27 of histone-3 and/or measuring the expression levels of EZH2 or YY-1. Agents useful for treating fibrosis or a fibrotic condition are also disclosed.
    Type: Grant
    Filed: November 2, 2009
    Date of Patent: August 18, 2015
    Assignee: University of Rochester
    Inventors: Jia Guo, Xin Lin, Steve Georas, Patricia Sime
  • Patent number: 9102913
    Abstract: The present invention provides biomatrix scaffolds for industrial scale dispersal.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: August 11, 2015
    Assignees: The University of North Carolina at Chapel Hill, PhoenixSongs Biologicals
    Inventors: Marsha Lynn Roach, Richard Harold Malavarca, Yunfang Wang, Lola Cynthia McAdams Reid
  • Patent number: 9096845
    Abstract: A method of preserving organisms in viable form, the method comprising: suspending organisms in a solution of electrospinnable polymer; drawing droplets of said solution through a spinneret; applying an electrostatic field to said droplets under electrospinning conditions; so as to form fibers having a diameter no greater than about 5 ?m within which distinct organisms are encapsulated in viable form.
    Type: Grant
    Filed: August 29, 2007
    Date of Patent: August 4, 2015
    Assignee: Technion Research & Development Foundation Limited
    Inventors: Jonathan Charles Kuhn, Eyal Zussman
  • Patent number: 9096846
    Abstract: A first cell containing at least one magnetic particle is provided and a second cell is also provided. The second cell is cultured in the presence of the first cell. An alternating magnetic field is applied to the first cell. The alternating magnetic field at least partially separates the first cell from the second cell.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: August 4, 2015
    Assignee: EMPIRE TECHNOLOGY DEVELOPMENT LLC
    Inventor: Masahiro Ueda
  • Patent number: 9097628
    Abstract: The present invention relates to a method for processing a wax-embedded biological sample, the use of poly(organosiloxane)s for liquefying the embedding medium of a wax-embedded biological sample and a kit for processing a wax-embedded biological sample.
    Type: Grant
    Filed: December 23, 2011
    Date of Patent: August 4, 2015
    Assignee: QIAGEN, GMbH
    Inventor: Martin Schlumpberger
  • Patent number: 9096831
    Abstract: A method is provided to functionally select cells with enhanced characteristics relevant to cell engraftment, including both spontaneous migration and directional migration towards specific chemo-attractants. The cells are preferably undifferentiated cells, such as mesenchymal stem cells. The method involves entrapping or encapsulating the cells in a biomaterial barrier, optionally inducing cell migration, and selecting cells that migrated through the barrier. The cells selected by this method have better migratory activities and enhanced in vivo engraftment to injured tissues when they are supplemented systemically.
    Type: Grant
    Filed: June 14, 2011
    Date of Patent: August 4, 2015
    Assignee: Versitech Limited
    Inventors: Barbara Pui Chan, Hoi Ling Wong, Mei Yi Wong, Godfrey Chi-Fung Chan, Zhen Fan Yang